Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in second-line RAS/BRAF mutant and MSS colorectal cancer

Phase 2

Zhejiang University